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Background/Aims: Gastric cancer is one of the most com-
mon malignant tumors worldwide with poor prognosis due 
to a lack of effective treatment modalities. Recent research 
showed that a long noncoding RNA named N-BLR modulates 
the epithelial-to-mesenchymal transition (EMT) process in 
colorectal cancer. However, the biological role of N-BLR in 
gastric cancer still remains to be explored. The aim of this 
study was to investigate the possibility of N-BLR as an EMT 
modulator in gastric cancer. Methods: The expression of N-
BLR was measured by quantitative polymerase chain reac-
tion in fresh gastric cancer tissue, paired adjacent normal 
tissues and cell lines. Fresh gastric tissues, paired samples 
obtained by surgery and clinical data were collected prospec-
tively. Knockdown of N-BLR was induced by small interfering 
RNA (siRNAs). Cell number and viability were assessed after 
treatment with siRNAs. The ability of N-BLR to promote me-
tastasis was measured using migration and invasion assays. 
Additionally, an inverse correlation between N-BLR and miR-
200c was measured by TaqMan microRNA assays. Western 
blotting was performed to detect EMT and apoptosis markers 
upon knockdown of N-BLR. Results: N-BLR expression was 
significantly elevated in gastric cancer cell lines and tissues 
compared to that in a normal gastric cell line and adjacent 
normal tissues (p<0.01). Two different siRNAs significantly 
reduced cell proliferation of gastric cancer cells compared to 
the siCT. siRNAs for N-BLR significantly suppressed migration 
and invasion in AGS and MKN28 cells. N-BLR expression 
was inversely correlated with miR-200c, which is known to 
regulate EMT. Conclusions: In this study, we confirmed N-
BLR as a regulator of the EMT process in gastric cancer. (Gut 
Liver 2019;13:421-429)
Key Words: RNA, long noncoding; Epithelial-to-mesenchymal 
transition; Gastric cancer
INTRODUCTION
Gastric cancer is the third leading cause of cancer death 
worldwide, with no significant biomarkers available for utiliza-
tion in clinical treatment.1 Recent studies have demonstrated 
that noncoding RNAs, including miRNA and long noncoding 
RNA (lncRNA), play important roles in gastric cancer progres-
sion and epigenetic gene expression at the transcript and post-
transcript levels.2-4 LncRNAs have drawn attention to the new 
class of noncoding RNA with lengths greater than 200 nucleo-
tides that act in critical roles in biological processes.5-7 Recently, 
some lncRNAs, such as H19, HOTAIR, and MEG3, have been 
found to engage in controlling tumorigenesis, tumor progres-
sion, and metastasis of diverse cancers.8-10 We previously an-
nounced that MALAT1 and HOTAIR can modulate invasion 
and migration in gastric cancer.10,11 Based on these results, we 
assumed that other lncRNAs are also involved in gastric carci-
nogenesis. 
N-BLR is a primate-specific lncRNA that has an important 
contribution to the mechanism of metastasis in colorectal can-
cer (CRC). In particular, microarray findings, including tran-
scription patterns of 2500+ human genome loci, showed N-BLR 
abundance in CRC and its role in the epithelial-to-mesenchymal 
transition (EMT) process.12 However, the functional role of N-
BLR in gastric cancer has not yet been discovered.
In this study, we examined the expression of N-BLR in gastric 
cancer and adjacent normal tissues. We investigated the effects 
of N-BLR on apoptosis, cell proliferation, colony formation, 
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and cell cycle as a carcinogenic indicator in gastric cancer. Ad-
ditionally, we analyzed N-BLR’s molecular mechanisms with 
regard to invasion and metastasis in vitro.
MATERIALS AND METHODS
1. Patients and tissue samples
Fresh gastric cancer tissue and paired adjacent gastric tissue 
samples were obtained from 38 patients who underwent surgi-
cal resection for gastric cancer at Severance Hospital, Yonsei 
University College of Medicine. All samples were frozen in 
liquid nitrogen immediately after resection and stored at –80°C 
until use. In addition, patient and lesion characteristics, com-
prising age, sex, Helicobacter pylori infection, tumor location, 
tumor differentiation, depth of tumor invasion, and lymph node 
metastasis, were obtained (Table 1). This study was approved by 
the Ethics Committee of Yonsei Hospital. Informed consent was 
obtained from all patients. Study protocol was reviewed and ap-
proved by the Institutional Review Board (IRB number: 4-2011-
0753). 
2. Cell lines and cell culture
A total of seven normal gastric and cancer cell lines were 
purchased from the Korean Cell Line Bank (Seoul National Uni-
versity, Seoul, Korea) or the American Type Culture Collection 
(Rockville, MD, USA). The cells were cultured in RPMI-1640 
medium (Thermo Scientific, Rockford, IL, USA) with 10% fetal 
bovine serum and 1% penicillin/streptomycin (Thermo Scien-
tific). These cells were maintained in a humidified atmosphere 
of 5% CO2 at 37°C. In addition, whole stomach cancer cells were 
used up to 30 passages; when cells were used up to 30 passages, 
they were discarded and new stocks were thawed.
3. Small interfering RNA (siRNA) transfection
For transfection, AGS, MKN 28, SNU719, and KATOIII cells 
(3×105) were seeded in 6-well culture plates and incubated 
at 37°C for 24 hours. The cells were transfected with targeted 
siRNA (lncRNA N-BLR, 50 μM; Invitrogen, Carlsbad, CA, USA) 
and RNAi negative control (50 μM, siCT; Invitrogen) using Li-
pofectamine 2000 reagent (Invitrogen) following the manufac-
turer’s protocol. The N-BLR siRNA target sequences were as fol-
lows: siN-BLR1 sense, UGUGGGAUGGUAGAGAGCAGUCUUU 
and antisense, AAAGACUGCUCUCUACCAUCCCAGA; siN-BLR2 
sense, GCUCAAAUCUACAGGACAAUU and antisense, AAUU 
GUCCUGUAGAUUUGAGC.
4. Total RNA extraction and quantitative real-time reverse 
transcription polymerase chain reaction
Total RNA was extracted from gastric cancer tissues and cell 
lines using TRIzol reagent (Invitrogen). RNA was measured using 
a Nanodrop (ND-100; NanoDropTechnologies Inc., Wilmington, 
DE, USA). Purity was confirmed based on the 260/280 nm ratio, 
Table 1. Patient and Lesion Characteristics According to the Level of 
N-BLR Expression
Variable
N-BLR expression*
p-value
Low High
Age, yr 0.746 
   <65 10 (52.6)  9 (47.4)
   ≥65  9 (47.4) 10 (52.6)
Sex >0.999
   Male 12 (63.2) 12 (63.2)
   Female  7 (36.8)  7 (36.8)
Helicobacter pylori infection† 0.637 
   Absent 5 (55.6) 3 (37.5)
   Present 4 (44.4) 5 (62.5)
Location 0.798 
   Upper third 2 (10.5) 1 (5.3)
   Middle third 8 (42.1)  7 (36.8)
   Lower third 9 (47.4) 11 (57.9)
Depth of tumor invasion 0.461 
   T1&T2  4 (21.1)  6 (37.6)
   T3&T4 15 (78.9) 13 (68.4)
Lymph node metastasis 0.097 
   Absent  5 (26.3) 10 (52.6)
   Present 14 (73.7)  9 (47.4)
Lymphovascular invasion 0.746 
   Absent  9 (47.4) 10 (52.6)
   Present 10 (52.6)  9 (47.4)
Stage‡ 0.105 
   I, II 7 (36.8) 12 (63.2)
   III 12 (63.2)  7 (36.8)
Lauren's classification 0.127 
   Intestinal   8 (42.1) 14 (7.37)
   Diffuse 10 (52.6)  4 (21.1)
   Mixed 1 (5.3) 1 (5.3)
Differentiation 0.051 
   AWD or AMD 9 (47.4) 11 (57.9)
   APD 3 (15.8)  7 (36.8)
   SRC 7 (36.8) 1 (5.3)
Serum CEA value, ng/mL 0.693 
   ≤5 14 (73.7) 16 (84.2)
   >5 5 (26.3)   3 (15.8)
Serum CA19-9 value, U/mL >0.999
   ≤37 18 (94.7) 17 (89.5)
   >37 1 (5.3)  2 (10.5)
Data are presented as number (%).
AWD, well-differentiated adenocarcinoma; AMD, moderately differ-
entiated adenocarcinoma; APD, poorly differentiated adenocarcino-
ma; SRC, signet ring cell carcinoma; CEA, carcinoembryonic antigen; 
CA19-9, carbohydrate antigen 19-9.
*Patients were classified into two groups according to the median 
N-BLR expression; †Status of H. pylori infection was missing in 21 
patients; ‡Stage was classified according to the 7th edition of the 
American Joint Cancer Committee/Union Internationale Contre le 
Cancer. 
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and products were loaded on 1% agarose gel. For cDNA synthe-
sis, 2.0 μg of RNA was reverse transcribed using SuperScriptTM 
II (Invitrogen) following the manufacturer’s protocol. The rela-
tive level of N-BLR was measured through real-time polymerase 
chain reaction (PCR) using iQ SYBR Green Supermix (Applied 
Biosystems Inc., Carlsbad, CA, USA). For miRNA analysis, 10 ng 
of total RNA were used for cDNA synthesis with RT primers for 
miR-200c-3p and U6 snRNA via TaqMan MicroRNA Reverse 
Transcription Kit (ThermoFisher Scientific, Waltham, MA, USA) 
following the manufacturer’s protocol. Real-time PCR was car-
ried out as mentioned above, using TaqMan microRNA assays 
(#002300 and #001973, ThermoFisher Scientific). The Ct value 
of the sample was normalized to U6 expression, and the 2–ΔΔCt 
value was calculated. Target sequences for N-BLR and U6 were 
as follows: N-BLR sense, GTAGCCGAATTGGGGATTTT and 
antisense, CGGGCTTGATCGTACAATTT; U6 sense, CTCGCTTCG-
GCAGCACA and antisense, AACGCTTCAGGAATTTGCGT.
5. Cell proliferation analysis
Gastric cancer cells were transfected with 50 μM siN-BLRs 
from 0 to 72 hours. Cell proliferation was detected using a 
CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(MTS assay; Promega, Madison, WI, USA) in 96-well culture 
plates at specified time intervals. The number of viable cells was 
allowed to react with MTS reagent for 1 hour in the dark. The 
amount of the reaction was measured with a spectrophotometric 
plate reader set at 490 nm (MultiskanTM Microplate Photometer; 
Thermo Scientific).
6. Scratch wound healing assay and invasion assay
AGS cells and MKN28 cells transfected with siN-BLRs or siCT 
were re-seeded in 6-well culture plates. When cells reached an 
approximate 60% to 80% confluency, the bottom of each well 
was scratched using a P-20 tip. The width of the scratched cells 
was measured at 0 and 24 hours under a bright-field micro-
scope. For the invasion assay, using the same cell line and con-
ditions above, cells were replated on BD BioCoat transwells (BD 
Biosciences, San Jose, CA, USA) following the manufacturer’s 
protocol. After 24 hours, non-invading cells within the cham-
ber were removed, and the upper layer of the trans-well was 
wiped with a cotton swab. The membrane of the bottom part of 
the upper chamber was fixed with 5% acetaldehyde buffer and 
stained with crystal violet solution. The invading cells on the 
membrane were counted under a bright-field microscope.
7. Cell cycle analysis and apoptosis analysis
Transfected AGS cells and MKN28 cells were washed with 
PBS and fixed with 75% ethanol at –20°C overnight. Cells were 
resuspended in PBS and treated with RNase for 30 minutes at 
room temperature. The nuclei of the fixed cells were stained 
with 50 mg/mL PI (Sigma, St. Louis, MO, USA) in the dark for 
20 minutes. Cell cycle phases were determined via flow cytom-
etry (BD Biosciences). For apoptosis analysis, the same two gas-
tric cancer cell lines were washed with PBS and resuspended in 
1× binding buffer (BD Biosciences). Fluorescein isothiocyanate 
(FITC), Annexin V, and propidium iodide staining was con-
ducted with the FITC Annexin V detection kit (BD biosciences) 
according to the manufacturer’s protocol. The rate of apoptosis 
was measured using flow cytometry (BD Biosciences).
8. Soft agar colony formation assay
To analyze tumorigenicity in vitro, base and top agarose gels 
were coated in 96-well culture plates using CytoSelectTM 96-
Well Cell Transformation Assay (Cell Biolabs, Inc). Then, 1.5 
mL of 2X DMEM containing 1% agarose was poured into each 
well as a base layer. After 1 hour of solidification, the trans-
fected cells were resuspended in 2X DMEM containing 0.7% 
agarose as a top layer and maintained in 37°C incubator for 2 
to 3 weeks. After daily observation, colonies were counted using 
bright field microscopy.
9. Western blot
Transfected cells with siN-BLRs or siCT were lysed in 1X RIPA 
buffer (Cell Signaling Technology, Danvers, MA, USA) contain-
ing protease inhibitor. Isolated proteins were loaded onto 8% to 
15% SDS–polyacrylamide gel electrophoresis and transferred to 
a polyvinylidene difluoride membrane (GE Healthcare, Piscat-
away, NJ, USA). The membrane was blocked for 1 hour at room 
temperature in tris–phosphate buffer containing 0.1% Tween 
20 with 5% BSA (BD biosciences), before being incubated with 
primary antibodies at 4°C overnight. The following primary an-
tibodies were used for Western blot analysis: epithelial marker 
E-cadherin (1:1,000; BD Biosciences), mesenchymal marker N-
cadherin (1:1,000; BD Biosciences), vimentin (1:200; Santa Cruz 
Biotechnology, Dallas, TX, USA, sc-373717), ZEB1 (1:1,000; Cell 
Signaling Technology), Snail (1:1,000; Cell Signaling Technol-
ogy), PARP (1:1,000; Cell Signaling Technology, #9542), bcl-
xl (1:1,000; Cell Signaling Technology, #2764), Bax (1:1,000; 
Santa Cruz Biotechnology, sc-493), cytochrome c (1:1,000; BD 
Biosciences), and β-actin (1:5,000; Bioworld Technology, St. 
Louis Park, MN, USA, AP0060). The signal was developed in 
ECL solution (GenDEPOT, Barker, TX, USA) and exposed to an 
Image Quant LAS 4000 bio-molecular imager for time intervals 
between 10 seconds and 6 minutes.
10. Statistical analysis
All analytical data for continuous variables are presented as 
the mean±standard error. Categorical variables were demon-
strated using proportions. Statistical tests comprised the t-test, 
chi-square test, and Fisher exact test. Based on the median of 
N-BLR expression, the expressions of N-BLR on gastric cancer 
were classified into low and high. The Kaplan-Meier method 
and log-rank test were used for survival analysis. A value of 
p<0.05 was regarded as a statistically significant difference for 
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Fig. 1. N-BLR was overexpressed in gastric cell lines and tissues. (A) The relative expression of N-BLR was upregulated in gastric cancer cells in-
cluding SNU719, KATOIII, AGS, MKN28, MKN45, and MKN74, compared to GES-1, a normal gastric cell line. (B) N-BLR expression was estimated 
in gastric cancer tissues (n=38) and paired adjacent noncancerous tissues (n=30). The expression of N-BLR was calculated by the 2–ΔΔCt method 
using U6 levels for normalization. These data represent the mean±SEM. *p<0.05 and †p<0.01 show a statistically significant difference compared 
with a scrambled control. N-BLR was not detected in eight adjacent noncancerous tissue samples by quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR).
Fig. 2. Knockdown of N-BLR expression suppressed gastric cancer cell proliferation. AGS, MKN28, MKN45, and SNU719 cells were transfected 
with siN-BLR1, siN-BLR2, or scrambled RNA (siCT, 50 µM), and expression of N-BLR (A) and cell viability were measured by MTS assay in gastric 
cancer cell lines (B). The data shown in the figures are from three independent experiments and represent the mean±SEM. *p<0.05 and †p<0.01 
show a statistically significant difference compared with a scrambled control.
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comparisons between groups. All statistical processes were ac-
complished using the statistical software SPSS for Windows 
version 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1. N-BLR is upregulated in gastric cancer cell lines and gas-
tric cancer tissues 
To further investigate the effect of N-BLR on gastric cancer, 
we observed the expression of N-BLR in normal epithelial gas-
tric GES-1 and six gastric cancer cell lines, SNU719, KATOIII, 
AGS, MKN28, MKN 45, and MKN74. The six gastric cancer cell 
lines revealed statistically significant elevation of N-BLR expres-
sion compared to GES-1 (Fig. 1A). The expression of N-BLR was 
significantly higher in cancer tissues than adjacent non-cancer 
tissues from 38 patients with gastric cancer (p<0.01) (Fig. 1B). 
2. Inhibition of N-BLRs by siRNAs down-regulated cell prolif-
eration of gastric cancer cell lines
We employed two different siRNA for N-BLR in AGS, 
MKN28, SNU719, and MKN45 cells to explore mechanisms of 
carcinogenesis. After treatment with siN-BLR1 or siN-BLR2 in 
gastric cancer cell lines, significantly reduced expression of N-
BLR was seen in AGS, MKN28, SNU719, and MKN45 compared 
to that of siCT in a dose-dependent manner (Fig. 2A). Both siN-
BLR1 and siN-BLR2 showed almost 50% knock-down at a con-
Fig. 3. siN-BLRs suppressed cell 
migration and invasion. (A) Wound 
healing assay was observed by mi-
croscopy at 0 and 24 hours. Scale 
bar refers to 100 μm. (B) Matrigel 
invasion assay was performed using 
an invasion chamber after knock-
down of N-BLR expression. After 
treatment with siRNAs, AGS and 
MKN28 cells were stained with 0.1% 
coomassie brilliant blue. Scale bar 
refers to 100 μm. (C) EMT markers 
were detected by immunoblotting 
in transfected AGS and MKN28 
cells. (D) The influence of transient 
transfection with siN-BLR on the 
miR-200 family. MiR-200c-3p was 
increased in both N-BLR small inter-
fering RNA (siRNA)-transfected cell 
lines compared with cells transfect-
ed with the scramble control. The 
data shown in the figures are from 
three independent experiments and 
represent the mean±SEM. *p<0.05 
and †p<0.01 show a statistically sig-
nificant difference compared with a 
scrambled control. 
EMT, epithelial-to-mesenchymal 
transition.
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centration of 50 μM in gastric cancer cell lines.
Next, we performed an MTS assay to assess viable cells after 
transfection with siRNAs for N-BLR. In four gastric cancer cell 
lines, both siN-BLR1 and siN-BLR2 significantly decreased cell 
viability at both 48 and 72 hours (Fig. 2B). 
3. Inhibition of N-BLR decreased migration and invasion of 
MKN28 and AGS cells
We explored the invasion and migration of gastric cancer 
cells using siRNAs for N-BLR. In the wound-healing assays, the 
migration of MKN28 and AGS cells was significantly inhibited 
by all siN-BLRs compared to that of the siCT (Fig. 3A). In a 
Matrigel invasion assay, all siRNAs significantly reduced inva-
sion, which is consistent with the wound healing assay results 
(Fig. 3B). After treatment of siN-BLRs, the expressions of ZEB1, 
Snail, N-cadherin, and Vimentin were reduced; however, E-
cadherin increased in both MKN28 and AGS cells (Fig. 3C). 
Treating siN-BLRs increased the level of miR-200c-3p (Fig. 3D) 
in both MKN28 and AGS cells. 
4. Suppression of N-BLR expression induces cell cycle ar-
rest and apoptosis
To follow up on our cell proliferation results, we evalu-
ated the role of N-BLR in cell cycle progression and apoptosis. 
Treatment with siN-BLRs promoted cell cycle arrest in the G2/
M phase and decreases the number of MKN28 cells in G0/G1 
(Fig. 4A). The same phenomenon was not observed in AGS 
cells. Furthermore, staining the cells with PI/Annexin V and 
siN-BLRs significantly increased apoptosis in AGS and MKN28 
cells (Fig. 4B). Both early and late apoptosis was increased by 
siN-BLRs. siN-BLRs increased cytochrome C, Bax, and PARP 
expression and decreased Bcl-XL expression in both cell lines 
(Fig. 4C). Next, we examined a soft agar colony formation assay 
to verify cellular anchorage-independent growth in vitro. The 
capability for colony formation decreased significantly in both 
siN-BLRs compared to siCT (Fig. 4D). Based on these results, we 
concluded that N-BLR induced cell cycle arrest and apoptosis 
and decreased colony formation correlated to cell proliferation 
in gastric cancer.
5. The relationships between N-BLR expression and clinico-
pathologic features in gastric cancer 
Age, sex, tumor location, depth of invasion, and lymph node 
metastasis did not differ between the N-BLR-low and N-BLR-
high groups. Histological differentiation tended to be different 
between the N-BLR-low and N-BLR-high groups, although the 
difference was not statistically significant (p=0.051). The pro-
portion of well- to moderately-differentiated adenocarcinomas 
was similar between the groups (N-BLR-low vs high: 45.0% 
vs 55.0%). However, poorly differentiated adenocarcinomas 
were mainly observed in the N-BLR-high group (N-BLR-low vs 
high: 30.0% vs 70.0%), while signet ring cell carcinoma was 
predominantly identified in the N-BLR-low group (N-BLR-low 
vs high: 87.5% vs 12.5%). In the subgroup analysis of tumors 
with undifferentiated histology (either poorly differentiated ad-
enocarcinoma or signet ring cell carcinoma), the histology did 
significantly differ between the N-BLR-low and N-BLR-high 
groups (p=0.025) (Table 1). In the survival analysis, disease-free 
and overall survival did not differ between the groups (disease-
free survival, p=0.905; overall survival, p=0.153) (Fig. 5).
DISCUSSION
Increasing evidence has shown that lncRNAs have vital roles 
in regulating biological processes.13 Many new lncRNAs have 
been found to be involved in the development and progression 
of cancer.14,15 Our previous work has aided in the discovery of a 
new lncRNA called N-BLR, which has been shown to be associ-
ated with tumor progression in CRC.12 In this study, we found 
that N-BLR was significantly involved in the development and 
progression of gastric cancer. N-BLR was elevated in gastric 
cancer compared to normal tissue. Knock-down of N-BLR 
inhibited the proliferation of four different gastric cancer cell 
lines, and this finding was supported by the observation that 
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Fig. 3. Continued.
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N-BLR inhibited apoptosis in AGS and MKN28 cell lines in our 
study. N-BLR promoted the EMT transition through regulation 
of E-cadherin, N-cadherin, ZEB1, and Snail. Knock-down of N-
BLR significantly increased the expression of miR-200c, which 
is known to inhibit EMT. These results suggest that N-BLR may 
be involved in cancer development and progression not only in 
CRC, but also in stomach cancer.
N-BLR is a pyknon-containing, primate-specific lncRNA 
located in the cytoplasm. In 2006, Rigoutsos et al.16 identified 
pyknons, which are a class of short DNA sequence motifs, in the 
human genome. A core property of pyknons is that they have 
multiple exact copies in the intergenic and intronic regions of 
the genome and in at least one mRNA. LncRNA containing 
pyknons was expected to play a role in regulation of biological 
processes.12,16 In fact, N-BLR plays a role in CRC according to a 
microarray targeting pyknon motifs.12
N-BLR was reported as a novel modulator of the EMT process 
and apoptotic pathway in CRC.12 N-BLR localizes to the cyto-
Fig. 4. N-BLR silencing induced apoptosis and cell cycle arrest. AGS and MKN28 cells were transfected with siCT or siN-BLRs, followed by cell-
cycle analysis using propidium iodide (PI) staining (A) and an apoptosis assay using PI/Annexin-V staining (B). (C) Western blotting analysis 
showed apoptotic and cell cycle markers in transfected AGS and MKN28 cells. (D) Soft agar colony formation was carried out with siN-BLRs 
stained with 0.5% crystal violet. Scale bar refers to 500 μm. The bar graph reveals the proportion of colony formation. The data represent the 
mean±SEM. *p<0.05 and †p<0.01 show a statistically significant difference compared with a scrambled control.
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plasm where it directly interacts with miR-141-3p and miR-
200c-3p, two members of the highly conserved miR-200 family 
known to inhibit EMT in CRC. Our observations showed that N-
BLR suppresses miR-200c and regulates EMT in gastric cancer. 
In addition, knock-down of N-BLR reduced markers involved in 
EMT, such as E-cadherin, N-cadherin, ZEB1, and Snail.
N-BLR acts as an inhibitor of apoptosis in CRC.12 Our ana-
lytical results show that knock-down of N-BLR significantly 
induced apoptosis in AGS and MKN28 cells. Knock-down of N-
BLR induced both early and late apoptosis, which subsequently 
reduced the proliferation of AGS and MKN28 cells. Our results 
also confirmed that knock-down of N-BLR can reduce tumori-
genesis by reducing colony formation. There are many studies 
that involve lncRNAs in gastric cancer apoptosis and contribute 
to the development of gastric cancer. Recently, studies have 
found that lncRNA expression, including that of HOXA11-AS, 
HOTAIR, LINC00673, TINCR, TUSC7, and MALAT1, significantly 
regulates apoptosis.10,11,17-20 However, the precise mechanism by 
which these lncRNAs are involved in apoptosis is still unclear. 
N-BLR was reported to mediate the switch from an epithelial 
to a mesenchymal cell phenotype by sequestering miR-141-3p 
and miR-200c-3p.12 In this, knock-down of N-BLR also induced 
a mesenchymal cell phenotype. siN-BLR reduced the expression 
of typical mesenchymal markers including ZEB1, Snail, N-cad-
herin, and Vimentin. However, siN-BLR was found to increase 
E-cadherin in both MKN28 and AGS cells. 
In CRC, the expression of N-BLR significantly affected the 
stage and prognosis.12 In the current study, the expression of N-
BLR was significantly up-regulated in cancer tissues compared 
to adjacent non-cancer tissues. However, we did not find a 
correlation between degree of N-BLR expression and prognosis 
in gastric cancer patients in survival and multivariate analysis. 
These differences can be explained with several reasons. First, 
the colon cancer study included many patients from two co-
horts, whereas our study included only 38 patients with gastric 
cancer. We think that the number of patients included in our 
study with gastric cancer was too small to have statistically sig-
nificant results. As a result, further study with a larger sample 
size of patients is needed. Second, stomach cancer has relatively 
high tumor heterogeneity compared to CRC.21
In conclusion, we found that N-BLR was related to apoptosis 
in gastric cancer carcinogenesis and promoted the EMT transi-
tion. Furthermore, this study also introduced the new N-BLR, 
which acts on the development and metastasis of gastric cancer. 
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Fig. 5. Kaplan-Meier plots represent disease-free survival and overall 
survival depending on the level of N-BLR in patients who underwent 
surgery.
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Based on the results of this study, we expect further studies to 
examine the use of N-BLR in the diagnosis and treatment of 
gastric cancer.
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